Citations

Mayo Clinic

Clear

1264 citation(s) found for "Xu, Nancy".

Schistosoma mansoni infection in eosinophil lineage–ablated mice
Swartz, Jonathan M. , Dyer, Kimberly D., Cheever, Allen W., Ramalingam, Thirumalai R. , Pesnicak, Lesley, Domachowske, Joseph B. , Lee, James J. , Lee, Nancy A., Foster, Paul S. , Wynn, Thomas A. , Rosenberg, Helene F.

Blood | June 14, 2006 | Volume: 108 | Issue: 7 | Pages: 2420-2427

10.1182/blood-2006-04-015933 | PMID 16772607 Get It

AbstractWe explore the controversial issue of the role of eosinophils in host defense against helminthic parasites using the established Schistosoma mansoni infection model in 2 novel mouse models of eosinophil lineage ablation (ΔdblGATA and TgPHIL). No eosinophils were detected in bone marrow of infected ΔdblGATA or TgPHIL mice, despite the fact that serum IL-5 levels in these infected mice exceeded those in infected wild type by approximately 4-fold. Liver granulomata from infected ΔdblGATA and TgPHIL mice were likewise depleted of eosinophils compared with those from their respective wild types. No eosinophil-dependent differences in granuloma number, size, or fibrosis were detected at weeks 8 or 12 of infection, and differential accumulation of mast cells was observed among the ΔdblGATA mice only at week 12. Likewise, serum levels of liver transaminases, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) increased in all mice in response to S mansoni infection, with no eosinophil-dependent differences in hepatocellular damage observed. Finally, eosinophil ablation had no effect on worm burden or on egg deposition. Overall, our data indicate that eosinophil ablation has no impact on traditional measures of disease in the S mansoni infection model in mice. However, eosinophils may have unexplored immunomodulatory contributions to this disease process.
Verification of Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis
Hall, Leslie, Doerr, Kelly A., Harmsen, William S. , Wengenack, Nancy L. , Roberts, Glenn D.

Journal of Clinical Microbiology | May 4, 2006 | Volume: 44 | Issue: 5 | Pages: 1921-1921

10.1128/jcm.44.5.1921.2006 | PMID 16672443 Get It

Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, Nancy, Chan, Julien K., Thamer, Mae , Melton, L. Joseph

Journal of Bone and Mineral Research | April 26, 2006 | Volume: 12 | Issue: 1 | Pages: 24-35

10.1359/jbmr.1997.12.1.24 | PMID 9240722 Get It

Abstract Osteoporotic fractures are a significant public health problem, resulting in substantial morbidity and mortality. Previous estimates of the economic burden of osteoporosis, however, have not fully accounted for the costs associated with treatment of nonhip fractures, minority populations, or men. Accordingly, the 1995 total direct medical expenditures for the treatment of osteoporotic fractures were estimated for all persons aged 45 years or older in the United States by age group, sex, race, type of fracture, and site of service (inpatient hospital, nursing home, and outpatient). Osteoporosis attribution probabilities were used to estimate the proportion of health service utilization and expenditures for fractures that resulted from osteoporosis. Health care expenditures attributable to osteoporotic fractures in 1995 were estimated at $13.8 billion, of which $10.3 billion (75.1%) was for the treatment of white women, $2.5 billion (18.4%) for white men, $0.7 billion (5.3%) for nonwhite women, and $0.2 billion (1.3%) for nonwhite men. Although the majority of U.S. health care expenditures for the treatment of osteoporotic fractures were for white women, one-fourth of the total was borne by other population subgroups. By site-of-service, $8.6 billion (62.4%) was spent for inpatient care, $3.9 billion (28.2%) for nursing home care, and $1.3 billion (9.4%) for outpatient services. Importantly, fractures at skeletal sites other than the hip accounted for 36.9% of the total attributed health care expenditures nationally. The contribution of nonhip fractures to the substantial morbidity and expenditures associated with osteoporosis has been underestimated by previous researchers.
Pivotal Advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response
Cormier, Stephania A. , Taranova, Anna G. , Bedient, Carrie E., Protheroe, Cheryl, Pero, Ralph, Dimina, Dawn, Ochkur, Sergei I. , O'Neill, K.R. , Colbert, Dana, Lombari, Theresa R, Constant, Stephanie L., McGarry, Michael P. , Lee, James J. , Lee, Nancy A., Nguyen, Thanh D.

Journal of Leukocyte Biology | April 14, 2006 | Volume: 79 | Issue: 6 | Pages: 1131-1139

10.1189/jlb.0106027 | PMID 16617160 Get It

Abstract Tumor-associated eosinophilia has been observed in numerous human cancers and several tumor models in animals; however, the details surrounding this eosinophilia remain largely undefined and anecdotal. We used a B16-F10 melanoma cell injection model to demonstrate that eosinophil infiltration of tumors occurred from the earliest palpable stages with significant accumulations only in the necrotic and capsule regions. Furthermore, the presence of diffuse extracellular matrix staining for eosinophil major basic protein was restricted to the necrotic areas of tumors, indicating that eosinophil degranulation was limited to this region. Antibody-mediated depletion of CD4+ T cells and adoptive transfer of eosinophils suggested, respectively, that the accumulation of eosinophils is not associated with T helper cell type 2-dependent immune responses and that recruitment is a dynamic, ongoing process, occurring throughout tumor growth. Ex vivo migration studies have identified what appears to be a novel chemotactic factor(s) released by stressed/dying melanoma cells, suggesting that the accumulation of eosinophils in tumors occurs, in part, through a unique mechanism dependent on a signal(s) released from areas of necrosis. Collectively, these studies demonstrate that the infiltration of tumors by eosinophils is an early and persistent response that is spatial-restricted. It is more important that these data also show that the mechanism(s) that elicit this host response occur, independent of immune surveillance, suggesting that eosinophils are part of an early inflammatory reaction at the site of tumorigenesis.
Cloning and Characterization of CYP51 from Mycobacterium avium
Pietila, Michael P., Vohra, Pawan K., Sanyal, Bharati, Wengenack, Nancy L. , Raghavakaimal, Sreekumar, Thomas, Charles F.

American Journal of Respiratory Cell and Molecular Biology | March 16, 2006 | Volume: 35 | Issue: 2 | Pages: 236-242

10.1165/rcmb.2005-0398oc | PMID 16543605 Get It

Abstract Mycobacterium avium complex (MAC) causes chronic lung disease in immunocompetent people and disseminated infection in patients with AIDS. MAC is intrinsically resistant to many conventional antimycobacterial agents, it develops drug resistance rapidly to macrolide antibiotics, and patients with MAC infection experience frequent relapses or the inability to completely eradicate the infection with current treatment. Treatment regimens are prolonged and complicated by drug toxicity or intolerances. We sought to identify biochemical pathways in MAC that can serve as targets for novel antimycobacterial treatment. The cytochrome P450 enzyme, CYP51, catalyzes an essential early step in sterol metabolism, removing a methyl group from lanosterol in animals and fungi, or from obtusifoliol in plants. Azoles inhibit CYP51 function, leading to an accumulation of methylated sterol precursors. This perturbation of normal sterol metabolism compromises cell membrane integrity, resulting in growth inhibition or cell death. We have cloned and characterized a CYP51 from MAC that functions as a lanosterol 14α-demethylase. We show the direct interactions of azoles with purified MAC-CYP51 by absorbance and electron paramagnetic resonance spectroscopy, and determine the minimum inhibitory concentrations (MICs) of econazole, ketoconazole, itraconazole, fluconazole, and voriconazole against MAC. Furthermore, we demonstrate that econazole has a MIC of 4 μg/ml and a minimum bacteriocidal concentration of 4 μg/ml, whereas ketoconazole has a MIC of 8 μg/ml and a minimum bacteriocidal concentration of 16 μg/ml. Itraconazole, voriconazole, and fluconazole did not inhibit MAC growth to any significant extent.
EOSINOPHILIC CYSTITIS IN ADULTS
ITANO, NANCY M. B., Malek, Reza S.

Journal of Urology | January 18, 2006 | Volume: 165 | Issue: 3 | Pages: 805-807

10.1016/s0022-5347(05)66531-7 Get It

ELECTRON BEAM COMPUTERIZED TOMOGRAPHY ASSESSMENT OF IN VIVO SINGLE KIDNEY GLOMERULAR FILTRATION RATE AND TUBULAR DYNAMICS DURING CHRONIC PARTIAL UNILATERAL URETERAL OBSTRUCTION IN THE PIG
Itano, Nancy B., SHERRILL, L. E., Lerman, Lilach O. , Corica, Federico A., Husmann, Douglas A. , Häuser, M. , Romero-Benavides, Juan Carlos

Journal of Urology | January 18, 2006 | Volume: 166 | Issue: 6 | Pages: 2530-2535

10.1016/s0022-5347(05)65629-7 Get It

Polypropylene Mesh Tape for Stress Urinary Incontinence: Complications of Urethral Erosion and Outlet Obstruction
SWEAT, SUSAN D., Itano, Nancy B., Bushman, Wade , Gruenenfelder, Jennifer, McGuire, Edward J., Lightner, Deborah J., Clemens, J. Quentin

Journal of Urology | January 17, 2006 | Volume: 168 | Issue: 1 | Pages: 144-146

10.1016/s0022-5347(05)64848-3 Get It

Long Term Use of Megestrol Acetate by Cancer Survivors for the Treatment of Hot Flashes
Quella, Susan K., Loprinzi, Charles L. , Sloan, Jeff A. , Vaught, Nancy L., DeKrey, Wanda L., Fischer, Tammy, Finck, Gwen, Pierson, Namali, Pisansky, Thomas M.

Journal of Urology | January 17, 2006 | Volume: 161 | Issue: 1 | Pages: 360-360

10.1016/s0022-5347(01)62161-x Get It

Real-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing
Espy, Mark J., Uhl, J. R., Sloan, Lynne M., Buckwalter, Seanne P., Jones, Mary F. , Vetter, Emily A., Yao, Joseph D. , Wengenack, Nancy L. , Rosenblatt, Jon E., Cockerill, Franklin R., Smith, Thomas F.

Clinical Microbiology Reviews | January 17, 2006 | Volume: 19 | Issue: 1 | Pages: 165-256

10.1128/cmr.19.1.165-256.2006 | PMID 16418529 Get It

SUMMARY Real-time PCR has revolutionized the way clinical microbiology laboratories diagnose many human microbial infections. This testing method combines PCR chemistry with fluorescent probe detection of amplified product in the same reaction vessel. In general, both PCR and amplified product detection are completed in an hour or less, which is considerably faster than conventional PCR detection methods. Real-time PCR assays provide sensitivity and specificity equivalent to that of conventional PCR combined with Southern blot analysis, and since amplification and detection steps are performed in the same closed vessel, the risk of releasing amplified nucleic acids into the environment is negligible. The combination of excellent sensitivity and specificity, low contamination risk, and speed has made real-time PCR technology an appealing alternative to culture- or immunoassay-based testing methods for diagnosing many infectious diseases. This review focuses on the application of real-time PCR in the clinical microbiology laboratory.